Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8431 to 8445 of 8944 results

  1. Lower urinary tract symptoms in men, trans and non-binary people with a prostate: assessment and management (update)

    Discontinued Reference number: GID-NG10300

    NICE guideline
    Discontinued

  2. Non-bisphosphonates for treating osteoporosis [ID901]

    Discontinued Reference number: GID-TA10072

    Technology appraisal guidance
    Discontinued

  3. Ganaxolone for adjunctive treatment of epilepsy associated with tuberous sclerosis complex with CDKL5 deficiency disorder [TSID12126]

    In development Reference number: GID-TA11697 Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments [ID6309]

    In development Reference number: GID-TA11546 Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Tislelizumab with chemotherapy for untreated unresectable or metastatic gastric or gastro-oesophageal junction cancer [ID6157]

    In development Reference number: GID-TA11092 Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Violence and aggression: short-term management in mental health, health and community settings

    Discontinued Reference number: GID-NG10397

    NICE guideline
    Discontinued

  7. Ipatasertib with fulvestrant for treating oestrogen-receptor positive HER2-negative advanced breast cancer after CDK 4/6 and aromatase inhibitor treatment [ID12194]

    In development Reference number: GID-TA11771 Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Cendakimab for treating eosinophilic oesophagitis in people 12 years TS ID 12088

    Discontinued Reference number: GID-TA11702

    Technology appraisal guidance
    Discontinued

  9. Niraparib with dostarlimab for maintenance treatment of advanced or recurrent endometrial cancer [ID6316]

    In development Reference number: GID-TA11365 Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Abrocitinib for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3768]

    Discontinued Reference number: GID-TA10764

    Technology appraisal guidance
    Discontinued

  11. Treatments for non-small-cell lung cancer [ID6234]

    Discontinued Reference number: GID-TA11289

    Technology appraisal guidance
    Discontinued

  12. Glaucoma - lerdelimumab (CAT-152) [ID383]

    Discontinued Reference number: GID-TAG381

    Technology appraisal guidance
    Discontinued

  13. Tiragolumab with atezolizumab for untreated PD-L1-positive advanced non-small-cell lung cancer [ID5122]

    In development Reference number: GID-TA11021 Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Soticlestat for treating seizures associated with Dravet syndrome in people 2 years and over TSID 12091

    In development Reference number: GID-TA11679 Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Pembrolizumab with lenvatinib and chemotherapy for untreated advanced gastro-oesophageal junction cancer [TSID11861]

    In development Reference number: GID-TA11345 Expected publication date: TBC

    Technology appraisal guidance
    In development